502 related articles for article (PubMed ID: 24010489)
1. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
2. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
3. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
[TBL] [Abstract][Full Text] [Related]
6. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
7. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
Lombard CW; Jöns O; Bussadori CM
J Am Anim Hosp Assoc; 2006; 42(4):249-61. PubMed ID: 16822763
[TBL] [Abstract][Full Text] [Related]
9. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
[TBL] [Abstract][Full Text] [Related]
10. Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.
Vollmar AC; Fox PR
J Vet Intern Med; 2016; 30(2):553-9. PubMed ID: 26936799
[TBL] [Abstract][Full Text] [Related]
11. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
O'Grady MR; Minors SL; O'Sullivan ML; Horne R
J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
[TBL] [Abstract][Full Text] [Related]
13. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
Boswood A; McEwan JD; French A; Little C; Swift S; Smith S; Patteson M
Vet Rec; 2003 Oct; 153(14):439-40. PubMed ID: 14582738
[No Abstract] [Full Text] [Related]
14. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
[TBL] [Abstract][Full Text] [Related]
16. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
Boswood A; Gordon SG; Häggström J; Vanselow M; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation.
Morgan KRS; Monteith G; Raheb S; Colpitts M; Fonfara S
Vet J; 2020 Sep; 263():105518. PubMed ID: 32928487
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
[TBL] [Abstract][Full Text] [Related]
20. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
